ProMetic Life Sciences Inc. (TSE:PLI – Get Free Report) shot up 0.2% during trading on Tuesday . The stock traded as high as C$13.72 and last traded at C$13.60. 921 shares were traded during trading, a decline of 88% from the average session volume of 8,002 shares. The stock had previously closed at C$13.57.
ProMetic Life Sciences Price Performance
The company has a debt-to-equity ratio of 37.47, a current ratio of 4.06 and a quick ratio of 3.66. The stock has a 50 day simple moving average of C$13.60. The stock has a market capitalization of C$317.06 million and a P/E ratio of -0.22.
ProMetic Life Sciences Company Profile
Prometic Life Sciences Inc operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals.
Further Reading
- Five stocks we like better than ProMetic Life Sciences
- How to Calculate Retirement Income: MarketBeat’s Calculator
- NVIDIA’s Blackwell Chips Set for Arizona Manufacturing by TSMC?
- Buy P&G Now, Before It Sets A New All-Time High
- Okta: Bullish Signals Suggest a Market Reversal Is Underway
- How to Calculate Stock Profit
- BlackRock Makes Waves With $12B Private Credit Acquisition
Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
